<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>African Americans (AAs) have the highest incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> of any American ethnic group </plain></SENT>
<SENT sid="2" pm="."><plain>Survival from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in AAs is lower than in Caucasians, and the mean age of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development in AAs is younger </plain></SENT>
<SENT sid="3" pm="."><plain>The AA community also has a high rate of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e>, accounting for 50.3% of <z:hpo ids='HP_0000001'>all</z:hpo> cases despite making up only 13.6% of the population </plain></SENT>
<SENT sid="4" pm="."><plain>This retrospective cohort study identified 17 AA HIV patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The patients were matched with 42 HIV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (controls), based on age, sex, and TNM stage </plain></SENT>
<SENT sid="6" pm="."><plain>Data were obtained from 3 hospitals in New Jersey: St </plain></SENT>
<SENT sid="7" pm="."><plain>Michael's Medical Center, Trinitas Medical Center and St </plain></SENT>
<SENT sid="8" pm="."><plain>Joseph's Medical Center </plain></SENT>
<SENT sid="9" pm="."><plain>The age, sex, HIV status, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site, stage, <z:e sem="disease" ids="C0242510" disease_type="Mental or Behavioral Dysfunction" abbrv="">drug usage</z:e>, <z:hpo ids='HP_0012115'>Hepatitis</z:hpo> C status, and survival outcome of subjects and controls were compared </plain></SENT>
<SENT sid="10" pm="."><plain>Data from the Surveillance Epidemiology &amp; End Results (SEER) specific to AAs were also compared </plain></SENT>
<SENT sid="11" pm="."><plain>The mean age of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis was younger, 50.7 years (median: 52 years, range: 35-71 years), versus 59.42 years (median: 66 years) (P &lt; 0.0001) in the SEER AA population </plain></SENT>
<SENT sid="12" pm="."><plain>Of the patients, 29.4% were diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> at less than 45 years of age, versus only 6.35% of the SEER AA population (P &lt; 0.0002) </plain></SENT>
<SENT sid="13" pm="."><plain>The male-to-female ratio was 11:6 </plain></SENT>
<SENT sid="14" pm="."><plain>Seven individuals used IV drugs, and 7 had <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C </plain></SENT>
<SENT sid="15" pm="."><plain>The mean CD4+ T-cell count was 510.81 cells/mm(3) (median 419) </plain></SENT>
<SENT sid="16" pm="."><plain>At the time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis, the average duration of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> was 7.6 years (range 0-22.4 years).Of patients, 87.5% had left-sided <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, versus 57.55% of the SEER population (P &lt; 0.024) </plain></SENT>
<SENT sid="17" pm="."><plain>Of the patients, 52.94% had stage III-IV, at diagnosis, versus 43.84% in SEER </plain></SENT>
<SENT sid="18" pm="."><plain>There was no statistically significant survival difference between the cases and controls </plain></SENT>
<SENT sid="19" pm="."><plain>In our cohort of HIV-infected AA's with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, the staging and outcome of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> did not appear to be affected by the degree of immunosuppression </plain></SENT>
<SENT sid="20" pm="."><plain>HIV-infected AA with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> presented with a higher percentage of left-sided <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> than AA's without HIV </plain></SENT>
<SENT sid="21" pm="."><plain>Additionally, AAs with HIV tended to be younger at the time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis </plain></SENT>
<SENT sid="22" pm="."><plain>Our findings suggest that screening for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> should be offered to HIV-infected AAs before the age of 45, and that sigmoidoscopy with fecal occult blood testing might be an acceptable screening modality </plain></SENT>
<SENT sid="23" pm="."><plain>However, the exact age of initiation, optimal frequency, and preferred method of screening (colonoscopy vs. sigmoidoscopy) in this population requires further study </plain></SENT>
</text></document>